Genavia Therapeutics Ltd., Origen Therapeutics Inc., Symphogen deal

The partners will develop transgenic chickens which produce human antibodies for cancer and infectious and autoimmune diseases. Origen will provide its avian transgenic technology, and Symphogen will use its Symplex technology to create recombinant human mAbs and polyclonal antibody therapeutics. The companies will share development costs and resulting IP. Origen will receive an undisclosed upfront payment and is eligible for development milestones. Symphogen may purchase exclusive rights to the transgenic chickens for certain products. Each company is eligible for royalties on the therapeutics developed by the partner. ...